Hennion & Walsh Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66M	Buy	30,485 +4,407	+17%	+$232K	0.05%	431
2026 Q1	$1.24M	Sell	26,078 -1,633	-6%	-$86.1K	0.04%	460
2025 Q4	$1.45M	Buy	27,711 +3,751	+16%	+$225K	0.05%	422
2025 Q3	$1.55M	Sell	23,960 -436	-2%	-$25K	0.06%	401
2025 Q2	$1.19M	Sell	24,396 -15,561	-39%	-$602K	0.05%	456
2025 Q1	$1.36M	Sell	39,957 -4,348	-10%	-$184K	0.06%	389
2024 Q4	$1.74M	Buy	44,305 +3,737	+9%	+$176K	0.08%	319
2024 Q3	$1.91M	Buy	40,568 +5,567	+16%	+$282K	0.09%	290
2024 Q2	$1.89M	Buy	35,001 +18,125	+107%	+$1.05M	0.1%	259
2024 Q1	$1.15M	Buy	16,876 +411	+2%	+$29.4K	0.06%	390
2023 Q4	$1.03M	Buy	16,465 +1,150	+8%	+$63.6K	0.06%	399
2023 Q3	$695K	Buy	15,315 +7,235	+90%	+$374K	0.04%	440
2023 Q2	$454K	Buy	+8,080	New	+$458K	0.03%	533

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Hennion & Walsh Asset Management's CRSP Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its CRISPR Therapeutics (CRSP) stake by 17% in Q2 2026, buying an estimated $232K and bringing the position to 30,485 shares worth $1.66M. The position accounts for 0.05% of the portfolio, ranked #431.

Hennion & Walsh Asset Management first reported a position in CRSP in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.91M in Q3 2024. 54 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Hennion & Walsh Asset Management held 30,485 shares of CRISPR Therapeutics worth $1.66M as of Q2 2026.
Hennion & Walsh Asset Management bought 4,407 CRISPR Therapeutics shares in Q2 2026, an estimated $232K.
CRISPR Therapeutics made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #431 holding.
Hennion & Walsh Asset Management first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 13 quarters since.
Hennion & Walsh Asset Management's CRISPR Therapeutics position peaked at $1.91M in Q3 2024.
54 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.